AACR Special Conference: Cancer Epigenomics
October 6-8, 2022
Renaissance Washington D.C.
Scott A. Armstrong, Dana-Farber Cancer Institute, Boston, Massachusetts
Howard Y. Chang, Stanford University, Stanford, California
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, Michigan
Margaret A. Goodell, Baylor College of Medicine, Houston, Texas
Cigall Kadoch, Dana-Farber Cancer Institute, Boston, Massachusetts
The epigenome regulates all cellular processes allowing the timely expression of our genetic information. Alterations of epigenetic processes have recently been shown to be at the core of several intractable malignancies and represent a previously unsuspected new paradigm of cancer. In contrast to oncogenic genetic mutations, epigenetic modifications of DNA and histones are reversible, and targeting specific epigenetic players is an emerging area of therapeutics. While broad epigenetic changes in cancer cells have been identified, distinguishing epigenetic changes that drive cancer is critical to identifying therapeutic targets. This conference on cancer epigenomics will not only cover the fundamental concepts, but cutting-edge developments and advances made in our understanding of the 3D genome including chromatin architecture, chromatin complexes, chromatin-associated RNA, histone modifications, and gene regulation specifically as they pertain to oncogenic mechanisms and new therapeutic opportunities in human cancer.
Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available